NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Ascending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
69238-1017-03 | 69238-1017 | Isotretinoin | Isotretinoin | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Oct. 2, 2017 | In Use | |
50242-0103-01 | 50242-0103 | polatuzumab vedotin | POLIVY | 30.0 mg/1.88mL | Immunotherapy | Drug Antibody Conjugate | CD79b | Intravenous | Sept. 18, 2020 | In Use | |
76075-0102-01 | 76075-0102 | Carfilzomib | Kyprolis | 30.0 mg/15mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | July 15, 2016 | In Use | |
50242-0142-01 | 50242-0142 | Mosunetuzumab | Lunsumio | 30.0 mg/30mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Dec. 22, 2022 | In Use | |
51144-0030-01 | 51144-0030 | ENFORTUMAB VEDOTIN | PADCEV | 30.0 mg/3mL | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | Intravenous | Dec. 18, 2019 | In Use | |
47781-0593-07 | 47781-0593 | paclitaxel | Paclitaxel | 30.0 mg/5mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec. 27, 2017 | Aug. 1, 2020 | No Longer Used |
67457-0471-52 | 67457-0471 | Paclitaxel | Paclitaxel | 30.0 mg/5mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 7, 2014 | Feb. 28, 2021 | No Longer Used |
00069-0079-01 | 00069-0079 | Paclitaxel | Paclitaxel | 30.0 mg/5mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 30, 2011 | Dec. 31, 2016 | No Longer Used |
58468-0357-01 | 58468-0357 | Alemtuzumab | Campath | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD52 | Intravenous | Nov. 30, 2009 | In Use | |
58468-0357-03 | 58468-0357 | Alemtuzumab | Campath | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD52 | Intravenous | Nov. 30, 2009 | In Use | |
50242-0145-01 | 50242-0145 | Pertuzumab | Perjeta | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | June 8, 2012 | In Use | |
50419-0208-01 | 50419-0208 | Radium Ra 223 dichloride | Xofigo | 30.0 uCi/mL | Chemotherapy | Radiopharmaceutical | Radium 223 | Intravenous | May 20, 2013 | In Use | |
58468-7860-03 | 58468-7860 | Vandetanib | CAPRELSA | 300.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Oral | June 24, 2022 | In Use | |
76346-0073-01 | 76346-0073 | Mifepristone | Korlym | 300.0 mg/1 | Hormonal Therapy | Antiprogestin | Cortisol Receptor Blocker | Oral | Feb. 17, 2012 | In Use | |
76346-0073-02 | 76346-0073 | Mifepristone | Korlym | 300.0 mg/1 | Hormonal Therapy | Antiprogestin | Cortisol Receptor Blocker | Oral | Feb. 17, 2012 | In Use | |
72064-0130-30 | 72064-0130 | avapritinib | Ayvakit | 300.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Oral | Jan. 9, 2020 | In Use | |
00173-0915-13 | 00173-0915 | Niraparib | ZEJULA | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | June 27, 2023 | In Use | |
00173-0915-61 | 00173-0915 | Niraparib | ZEJULA | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | June 27, 2023 | In Use | |
69660-0203-91 | 69660-0203 | Rucaparib | Rubraca | 300.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec. 19, 2016 | July 31, 2025 | In Use |
00591-4390-96 | 00591-4390 | Mifepristone | Mifepristone | 300.0 mg/1 | Hormonal Therapy | Antiprogestin | Cortisol Receptor Blocker | Oral | Jan. 19, 2024 | In Use | |
59572-0740-07 | 59572-0740 | azacitidine | ONUREG | 300.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec. 18, 2020 | In Use | |
59572-0740-14 | 59572-0740 | azacitidine | ONUREG | 300.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sept. 1, 2020 | In Use | |
50419-0395-01 | 50419-0395 | Darolutamide | Nubeqa | 300.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | July 31, 2019 | In Use | |
50419-0395-72 | 50419-0395 | Darolutamide | Nubeqa | 300.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | March 3, 2021 | In Use | |
00310-7840-30 | 00310-7840 | Vandetanib | Caprelsa | 300.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Oral | July 25, 2011 | May 31, 2020 | No Longer Used |
Found 10,000 results in 11 milliseconds — Export these results